CTOs on the Move

Newport Healthcare

www.newporthealthcare.com

 
Newport Healthcare is changing the face of behavioral health services for teens, young adults and their families by providing sustainable healing.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

University Compounding Pharmacy

University Compounding Pharmacy is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Onco360 Pharmacy

Onco360 provides industry-leading Oncology Pharmacy services for Patients, Physicians, Pharma, Payers, & Hospitals. Learn more.

Cerevance

Cerevance is advancing a promising pipeline of new treatments for central nervous system diseases.

Kentucky Counseling Center

We provide counseling, psychiatry, and targeted case management for children and adults without the long wait times throughout Kentucky. Discover our services today.

UroGen

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.